Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro
- PMID: 18940013
- PMCID: PMC2584338
- DOI: 10.1186/1471-2407-8-304
Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro
Abstract
Background: Despite the advances made during decades of research, the mechanisms by which glioma is initiated and established remain elusive. The discovery of glioma stem cells (GSCs) may help to elucidate the processes of gliomagenesis with respect to their phenotype, differentiation and tumorigenic capacity during initiation and progression. Research on GSCs is still in its infancy, so no definitive conclusions about their role can yet be drawn. To understand the biology of GSCs fully, it is highly desirable to establish permanent and biologically stable GSC lines.
Methods: In the current study, GSCs were isolated from surgical specimens of primary and recurrent glioma in a patient whose malignancy had progressed during the previous six months. The GSCs were cryopreserved and resuscitated periodically during long-term maintenance to establish glioma stem/progenitor cell (GSPC) lines, which were characterized by immunofluorescence, flow cytometry and transmission electronic microscopy. The primary and recurrent GSPC lines were also compared in terms of in vivo tumorigenicity and invasiveness. Molecular genetic differences between the two lines were identified by array-based comparative genomic hybridization and further validated by real-time PCR.
Results: Two GSPC lines, SU-1 (primary) and SU-2 (recurrent), were maintained in vitro for more than 44 months and 38 months respectively. Generally, the potentials for proliferation, self-renewal and multi-differentiation remained relatively stable even after a prolonged series of alternating episodes of cryopreservation and resuscitation. Intracranial transplantation of SU-1 cells produced relatively less invasive tumor mass in athymic nude mice, while SU-2 cells led to much more diffuse and aggressive lesions strikingly recapitulated their original tumors. Neither SU-1 nor SU-2 cells reached the terminal differentiation stage under conditions that would induce terminal differentiation in neural stem cells. The differentiation of most of the tumor cells seemed to be blocked at the progenitor cell phase: most of them expressed nestin but only a few co-expressed differentiation markers. Transmission electron microscopy showed that GSCs were at a primitive stage of differentiation with low autophagic activity. Array-based comparative genomic hybridization revealed genetic alterations common to both SU-1 and SU-2, including amplification of the oncogene EGFR and deletion of the tumor suppressor PTEN, while some genetic alterations such as amplification of MTA1 (metastasis associated gene 1) only occurred in SU-2.
Conclusion: The GSPC lines SU-1 and SU-2 faithfully retained the characteristics of their original tumors and provide a reliable resource for investigating the mechanisms of formation and recurrence of human gliomas with progressive malignancy. Such investigations may eventually have major impacts on the understanding and treatment of gliomas.
Figures
Similar articles
-
A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.Mol Pharmacol. 2012 Sep;82(3):400-7. doi: 10.1124/mol.112.078402. Epub 2012 May 30. Mol Pharmacol. 2012. PMID: 22648970
-
[CDK1 expression and effects of CDK1 silencing on the malignant phenotype of glioma cells].Zhonghua Zhong Liu Za Zhi. 2007 Jul;29(7):484-8. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 18069625 Chinese.
-
MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.FASEB J. 2020 Apr;34(4):5128-5143. doi: 10.1096/fj.201802629RR. Epub 2020 Feb 17. FASEB J. 2020. PMID: 32067282
-
New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs.J Cell Physiol. 2014 Sep;229(9):1141-7. doi: 10.1002/jcp.24540. J Cell Physiol. 2014. PMID: 24374932 Review.
-
Targeting glioma stem cells: enough to terminate gliomagenesis?Chin Med J (Engl). 2011 Sep;124(17):2756-63. Chin Med J (Engl). 2011. PMID: 22040437 Review.
Cited by
-
Expression of metastasis-associated protein 3 in human brain glioma related to tumor prognosis.Neurol Sci. 2015 Oct;36(10):1799-804. doi: 10.1007/s10072-015-2252-8. Epub 2015 May 23. Neurol Sci. 2015. PMID: 26002011
-
MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway.Oncotarget. 2016 Jul 5;7(27):41505-41526. doi: 10.18632/oncotarget.9214. Oncotarget. 2016. PMID: 27166258 Free PMC article.
-
Astrocytoma-associated antigens - IL13Rα2, Fra-1, and EphA2 as potential markers to monitor the status of tumour-derived cell cultures in vitro.Cancer Cell Int. 2014 Aug 22;14:82. doi: 10.1186/s12935-014-0082-z. eCollection 2014. Cancer Cell Int. 2014. PMID: 25788865 Free PMC article.
-
Development of clinically relevant orthotopic xenograft mouse model of metastatic lung cancer and glioblastoma through surgical tumor tissues injection with trocar.J Exp Clin Cancer Res. 2010 Jun 29;29(1):84. doi: 10.1186/1756-9966-29-84. J Exp Clin Cancer Res. 2010. PMID: 20587035 Free PMC article.
-
Reciprocal regulation of integrin β4 and KLF4 promotes gliomagenesis through maintaining cancer stem cell traits.J Exp Clin Cancer Res. 2019 Jan 18;38(1):23. doi: 10.1186/s13046-019-1034-1. J Exp Clin Cancer Res. 2019. PMID: 30658712 Free PMC article.
References
-
- Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8. - PubMed
-
- Gilbertson RJ. Brain tumors provide new clues to the source of cancer stem cells: does oncology recapitulate ontogeny? Cell Cycle. 2006;5:135–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous